Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 31, 2007 Brian Orelli	GPC Takes a Pit Stop The biotech company pulls its New Drug Application for Satraplatin. There is something twisted about having to wait to get a drug to market because it's performing better than expected. Investors, take note.
The Motley Fool May 16, 2007 Brian Lawler	GPC's Next Cancer Drug? GPC Biotech prepares for its future as it awaits an FDA decision on its lead drug. Investors, take note.
The Motley Fool November 1, 2007 Brian Lawler	Achtung, GPC! The German biotech sector took a hit yesterday, after GPC Biotech and partner Pharmion announced that GPC's lead drug, satraplatin, had failed an important endpoint in phase 3 testing.
The Motley Fool June 27, 2007 Brian Lawler	Waiting on GPC Exciting development-stage drugmaker GPC's marketing partner files a European marketing application for its top drug.
The Motley Fool June 20, 2007 Brian Lawler	GPC Markets Itself GPC showcases itself at two investor conferences last week. The biotech's shares have nearly doubled off of its 52-week lows, following the announcement of successful phase 3 results and anticipation of FDA approval for its lead compound.
The Motley Fool November 9, 2007 Brian Lawler	GPC Regroups Pharma GPC Biotech updates investors following a surprising setback on its lead drug. Investors, take note.
The Motley Fool March 31, 2008 Brian Lawler	GPC Recaps a Tough Year Development-stage drugmaker GPC Biotech releases its year-end financial results after a 2007 in which the FDA depth-charged its lead drug.
BusinessWeek October 16, 2006 Gene G. Marcial	Spectrum Has A Rosy Glow When Spectrum Pharmaceuticals announced on Sept. 25 that results from the Phase 3 trials of its Satraplatin were "positive," its shares bolted.
The Motley Fool July 23, 2007 Brian Lawler	GPC's Date With the FDA A document released by the FDA outlines its concerns with GPC's lead drug. Investors, take note.
The Motley Fool August 10, 2007 Brian Lawler	GPC Picking Up the Pieces GPC Biotech announced second-quarter financial results last week, in the shadow of a setback; they are awaiting more data on a crucial drug candidate.
BusinessWeek November 3, 2003	Spectrum's New Cancer Weapons Several big investors have been buying little-known Spectrum Pharmaceuticals, which develops anticancer agents that have previous clinical data to back their efficacy and safety.
The Motley Fool July 25, 2007 Brian Lawler	GPC Must Wait An advisory panel recommends against approving GPC's lead drug right now. Investors, take note.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool May 2, 2011 Brian Orelli	Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror.
The Motley Fool April 27, 2011 Brian Orelli	Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
The Motley Fool March 4, 2010 Brian Orelli	Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool June 6, 2011 Luke Timmerman	Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off?
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool May 4, 2009 Robert Steyer	Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success?
The Motley Fool November 16, 2010 Luke Timmerman	Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug.
BusinessWeek July 25, 2005 Gene G. Marcial	Spectrum's Cancer Drugs Could be Winners Biotechs got battered earlier this year, but some investors are optimistic about Spectrum Pharmaceuticals because of the anticancer agents it has in advanced clinical trials.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument.
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
The Motley Fool September 28, 2010 Brian Orelli	Pfizer's Sutent Fails. Again! No surprise here.
The Motley Fool April 12, 2005 Brian Gorman	Genentech's Cancer Quest The company's achievements in lung cancer further strengthen its reputation as a cancer fighter. Would-be investors are best served by waiting patiently.
BusinessWeek June 21, 2004 Catherine Arnst	Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs.
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.
BusinessWeek June 16, 2011 Langreth & Cortez	When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates.
The Motley Fool August 6, 2007 Brian Orelli	Hopeful Investors Stoke Pharmion's Price Clinical trials to get a drug approved for new uses usually don't have the gusto that trials for the original New Drug Application have, but Pharmion results released last week have blown the stock price through the roof.
Chemistry World June 22, 2011 Sarah Houlton	US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe.
Nurse Practitioner October 2009 Wallace et al.	Shedding light on prostate cancer This article will discuss the risk factors, signs and symptoms, diagnosis of prostate cancer, and disease staging and grading, as well as necessary lab and diagnostic tests, treatment options and patient education.
Managed Care March 2007 Martin Sipkoff	Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails.
The Motley Fool November 20, 2007 Brian Orelli	Celgene Buys a Sales Force Pharmaceutical Celgene acquires Pharmion for $2.9 billion, hoping that Pharmion's two drugs in mid-to-late clinical trials will justify the purchase price in the not-too-distant future.
AskMen.com Jacob Franek	Prostate Cancer Overview Everything you wanted to know and more about prostate cancer in this three-part prostate cancer guide.
AskMen.com Jacob Franek	Prostate Cancer Treatment And Prevention Everything you wanted to know about prostate cancer in our three-part Prostate Cancer Guide.
AskMen.com	Good Health Care News New advice from the American Cancer Society puts a sharper focus on the risks of prostate cancer screening, emphasizing that annual testing can lead to unnecessary biopsies and treatments that do more harm than good.
AskMen.com	Cholesterol & The Prostate A new study suggests that men may be able to lower their risk of getting the most aggressive form of prostate cancer by keeping their cholesterol in a healthy range.
AskMen.com Jen Woodward	Prostate Cancer 101 Here are some of the basic facts about prostate cancer, along with what you can do to keep the C-word from gracing your medical chart.
American Family Physician May 15, 2005	Early Prostate Cancer: What You Should Know A patient hand-out on the disease, who is at risk, diagnosis and treatment options.
Pharmaceutical Executive February 1, 2013 William Looney	In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer.
The Motley Fool January 18, 2005 Charly Travers	Biotech Class of 2004 Hot drugs are leading to amazing stock performances. CoTherix... Eyetech Pharmaceuticals... Pharmion... etc.
Chemistry World November 4, 2015 Suzanne Howson	Oral delivery of anticancer drug Scientists in China have unveiled a way to deliver a platinum-based anticancer drug orally.
Chemistry World February 11, 2009 Lewis Brindley	Prostate Cancer Biomarker Could Speed Diagnosis US researchers have identified a compound in urine that could be used to detect prostate cancer - and also to distinguish between benign and invasive forms of the disease.
AskMen.com Jacob Franek	Prostate Cancer Symptoms, Screening & Diagnosis Despite the facts that prostate cancer is the No. 1 cancer occurring in men (aside from skin cancers) and the second leading cause of cancer death (behind lung cancer), many men are still unfamiliar with this highly treatable disease.